Resf1 is a compound G4 quadruplex-associated tumor suppressor for triple negative breast cancer.
Megan R MajochaDevin E JacksonNgoc-Han HaRuhul AminMarie PangrácováChristina R RossHoward Hua YangMaxwell Ping LeeKent W HunterPublished in: PLoS genetics (2024)
Patients with ER-negative breast cancer have the worst prognosis of all breast cancer subtypes, often experiencing rapid recurrence or progression to metastatic disease shortly after diagnosis. Given that metastasis is the primary cause of mortality in most solid tumors, understanding metastatic biology is crucial for effective intervention. Using a mouse systems genetics approach, we previously identified 12 genes associated with metastatic susceptibility. Here, we extend those studies to identify Resf1, a poorly characterized gene, as a novel metastasis susceptibility gene in ER- breast cancer. Resf1 is a large, unstructured protein with an evolutionarily conserved intron-exon structure, but with poor amino acid conservation. CRISPR or gene trap mouse models crossed to the Polyoma Middle-T antigen genetically engineered mouse model (MMTV-PyMT) demonstrated that reduction of Resf1 resulted in a significant increase in tumor growth, a shortened overall survival time, and increased incidence and number of lung metastases, consistent with patient data. Furthermore, an analysis of matched tail and primary tissues revealed loss of the wildtype copy in tumor tissue, consistent with Resf1 being a tumor suppressor. Mechanistic analysis revealed a potential role of Resf1 in transcriptional control through association with compound G4 quadruplexes in expressed sequences, particularly those associated with ribosomal biogenesis. These results suggest that loss of Resf1 enhances tumor progression in ER- breast cancer through multiple alterations in both transcriptional and translational control.
Keyphrases
- mouse model
- genome wide
- squamous cell carcinoma
- small cell lung cancer
- amino acid
- gene expression
- copy number
- transcription factor
- randomized controlled trial
- risk factors
- endoplasmic reticulum
- crispr cas
- estrogen receptor
- genome wide identification
- cardiovascular events
- single cell
- breast cancer cells
- risk assessment
- type diabetes
- climate change
- coronary artery disease
- free survival
- long non coding rna
- small molecule
- genome editing
- deep learning
- breast cancer risk
- heat shock protein
- protein protein